GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mersana Therapeutics Inc (NAS:MRSN) » Definitions » Growth Rank

Mersana Therapeutics (Mersana Therapeutics) Growth Rank : 4 (As of Apr. 26, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Mersana Therapeutics Growth Rank?

Mersana Therapeutics has the Growth Rank of 4.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.


Competitive Comparison of Mersana Therapeutics's Growth Rank

For the Biotechnology subindustry, Mersana Therapeutics's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mersana Therapeutics's Growth Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mersana Therapeutics's Growth Rank distribution charts can be found below:

* The bar in red indicates where Mersana Therapeutics's Growth Rank falls into.



Mersana Therapeutics Growth Rank Related Terms

Thank you for viewing the detailed overview of Mersana Therapeutics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Mersana Therapeutics (Mersana Therapeutics) Business Description

Traded in Other Exchanges
Address
840 Memorial Drive, Cambridge, MA, USA, 02139
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
Executives
Anna Protopapas director, officer: President and CEO MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Mohan Bala officer: SVP, Chief Development Officer C/O MERSANA THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Tushar Misra officer: Chief Manufacturing Officer 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Brian Deschuytner officer: Sr. VP, Finance & Product stgy 840 MEMORIAL DRIVE, CAMBRIDGE MA 01776
Ashish Mandelia officer: VP, Controller 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Timothy B Lowinger officer: Chief Scientific Officer 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Alejandra Carvajal officer: Chief Legal Officer C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Arvin Yang officer: Chief Medical Officer 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Hack Andrew A. F. director 300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Michael J. Kaufman officer: Sr VP Chmistry, Man & Control 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Allene M. Diaz director C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Eva M. Jack officer: CBO, Treasurer & Secretary 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Lawrence M Alleva director 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Scott D Sandell 10 percent owner

Mersana Therapeutics (Mersana Therapeutics) Headlines

From GuruFocus